Gerresheimer AG (GXI.DE)
| Previous Close | 102.00 |
| Open | 101.70 |
| Bid | 102.10 x 21100 |
| Ask | 102.20 x 8200 |
| Day's Range | 101.60 - 102.90 |
| 52 Week Range | 81.35 - 122.90 |
| Volume | |
| Avg. Volume | 113,360 |
| Market Cap | 3.533B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | 29.40 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.25 (1.23%) |
| Ex-Dividend Date | Jun 06, 2024 |
| 1y Target Est | N/A |
- CNW Group
Gerresheimer partners with RxCap to offer connected adherence solutions
Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has entered into a partnership with the US digital health company RxCap and acquired a minority stake. Under the terms of the agreement, Gerresheimer's subsidiary Centor will receive the exclusive distribution rights for pharmacies in the U.S. for adherence solutions by RxCap, consisting of connected prescription vial closure devices and complementary cloud-based softwa
- PR Newswire
Gerresheimer awarded EcoVadis Gold status again
Gerresheimer, an innovative provider of systems and solutions and a global partner for the pharma, biotech, and cosmetic industries, has once again been awarded Gold status by the ratings agency EcoVadis. EcoVadis assesses the performance of businesses on environmental, labor and human rights, ethical, and sustainable procurement criteria. More than 100,000 companies worldwide turn to EcoVadis for CSR performance reviews. Gerresheimer earned a spot in the top 5% of all companies assessed by EcoV
- ACCESSWIRE
Gerresheimer AG: Gerresheimer Continues Dynamic Growth in First Half of 2023
Gerresheimer, an innovative provider of systems and solutions and a global partner for the pharma and biotech industries, has continued its profitable growth, posting strong results for the first half of the year. Revenues grew organically, without foreign exchange rate effects, by 16.6% to reach EUR 957.4m. Adjusted EBITDA was EUR 185.2m.
